First Patient Dosed in Phase 2 Trial of Oral Treatment to Ease Inflammation in Parkinson’s
Alkahest announced the dosing of a first patient in the Phase 2 trial for its Parkinson’s therapy AKST4290, an oral…
Articles by Forest Ray PhD
Treating Stem Cells with Fasudil Eases Parkinson’s Symptoms in Mouse Model, Study Finds
Bone marrow stem cells treated with fasudil and administered via the nose (intranasal) to mice in a model of…
Number of Dopaminergic Neurons at Birth Could Affect Lifetime Parkinson’s Risk, Report Suggests
The number of dopamine-producing (dopaminergic) neurons at birth could influence a person’s lifetime risk of developing Parkinson’s disease, according…
Gut Bacteria Protects Against Alpha-Synuclein Buildup in Nerve Cells in Worm Model, Study Shows
A common gut bacteria called Bacilus subtilis (B. subtilis), which aids in digestion, shows the potential to counteract the…
Cerevel Therapeutics Initiates Phase 3 Program Testing Tavapadon for Improved Motor Function
Cerevel Therapeutics announced its launch of a series of Phase 3 clinical trials to evaluate its investigational therapy…
Affiris Announces Phase 2 Study of Potential Parkinson’s Vaccine
Affiris is preparing for a Phase 2 clinical trial to test Affitope (PD01A), an experimental medicine that, if successful,…
One-year Results in 2 Given Gene Therapy at Low Dose Showing Promise, Axovant Reports
Two Parkinson’s patients treated with AXO-Lenti-PD, an investigative gene therapy, in an ongoing clinical trial continue to show improvement…
Certain Impulse-Control Medications May Not Work for Parkinson’s Disease, Study Suggests
Medications used to manage impulse control disorders may not help Parkinson’s disease patients taking Mirapex (pramipexole)…
Excess Iron in Brain Cells Worsens Parkinson’s Symptoms, Mouse Study Shows
While excess iron in the brain often accompanies Parkinson’s disease, it remains unknown whether the iron overload actually causes…
Dosing Underway in Phase 1 Trial of AL101 for Potential Treatment of Parkinson’s, Other Disorders
Dosing has begun for healthy volunteers in a Phase 1 clinical trial of AL101, which has the potential to treat…